Anti-Human B7-H4 (VTCN1) (Clone CPTC-VTCN1-2) – Purified No Carrier Protein

VTCN1 synthetic peptide EGVLGLVHEFK

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FSAI171R-7D11 targets a non-modified peptide derived from human VTCN1 (EGVLGLVHEFK).

CPTC-VTCN1-2

VTCN1 (also known as B7-H4) is a coinhibitory molecule that negatively regulates the activation and proliferation of T cells, plays an important role in the proliferation, invasion, and metastasis of tumors, and is protective against type 1 diabetes and in organ transplantation¹. VTCN1 is a member of the B7/CD28 family which is generally involved in the activation of T cells and promoting immune tolerance. Translation of VTCN1 is strictly controlled in normal tissues, where VTCN1 RNA, but not protein, is widely detectable. However, VTCN1 protein is abnormally present in tumors, inflammation, and autoimmune diseases and is therefore a target of related immunotherapies. Several functional VTCN1 polymorphisms linked to increased risk of cancer have been identified. Additionally, increased VTCN1 protein abundance in tumor- associated macrophages is associated with shorter life expectancy².

FSAI171R-7D11 was generated in mouse using a non-modified peptide sequence of human VTCN1 (EGVLGLVHEFK)^3,4. FSAI171R-7D11 was developed for use in immuno-MRM assays and recognizes the EGVLGLVHEFK peptide as well as full-length recombinant VTCN1. The antibody does not work for detection in immunohistochemistry, immunofluorescence, or Reverse Phase Protein Array⁵. FSAI171R-7D11 can detect VTCN1 recombinant protein by Western blotting but does not detect VTCN1 in tissue or cell lysate samples.

VTCN1 RNA, but not protein, is widely expressed in most normal tissues. VTCN1 protein is detected in ovarian, breast, renal cell, endometrial, and non-small-cell lung cancers as well as immunosuppressive tumor-associated macrophages. VTCN1 is present on cell membrane surfaces, but a soluble form can also be found.

N/A

1 Wang JY, Wang WP. Cell Immunol. 347:104008. 2020.
2 Podojil JR, Miller SD. Immunol Rev. 276(1):40-51. 2017.
3 https://research.fredhutch.org/content/dam/stripe/paulovich/files/PaulovichLab_Mab_AvailableF orImmuno-MRM_11092020.pdf
4 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
5 https://antibodies.cancer.gov/detail/CPTC-VTCN1-2#CPTC-VTCN1-2-Background